Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Blood advances - 25 Aug 2026

Naji Nour Sabiha, Ahmedna Taha, Zeng Xinghan, An Yuju, Hemani Yashvi, Perkins Brandy, Thompson Zanshe, Nichakawade Tushar D, Wang Yanyan, Lee Bum Seok, Watson Evangeline, Chatzilygeroudi Theodora, Luo Li, Paun Bogdan, Klausner Melanie, Supeanu Teodora, Gojo Ivana, Ghiaur Gabriel, DeZern Amy E, Levis Mark J, Resar Linda, Jones Richard J, Peske J David, Karanika Styliani, Paul Suman, Karantanos Theodoros

Abstract excerpt

ABSTRACT: Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) with high-risk features including TP53 mutations have poor outcomes because of the lack of effective therapies. The atypical chemokine surface receptor C-C motif chemokine receptor-like 2 (CCRL2) is overexpressed in MDS and secondary AML compared with healthy hematopoietic cells, and we recently found that TP53-mutated MDS/AML and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Immunoconjugates

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Pyrroles

Share to Tumor Suppressor Protein p53

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 42160756
DOI: 10.1182/bloodadvances.2025019380
PMCID: PMC13499191

Genes

CCRL2
TP53
CD33

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.PMID 42160756Read ↗

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLSemantic proximity Read ↗

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLSemantic proximity Read ↗

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidineSemantic proximity Read ↗

CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>Semantic proximity Read ↗

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation blockSemantic proximity Read ↗

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity Read ↗

C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53.Semantic proximity Read ↗

The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemiaSemantic proximity Read ↗

IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cellsSemantic proximity Read ↗

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responsesSemantic proximity Read ↗

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLSemantic proximity Read ↗

CXCR2 As a Novel Target for Overcoming Resistance to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.